Following more than a year of restructuring and recalibration, Regulus Therapeutics Inc. is facing a new partial clinical hold placed by the FDA on its phase I test of RGLS-4326, an oligonucleotide it's developing for the treatment of autosomal dominant polycystic kidney disease (ADPKD). 

DUBLIN – Shares in Polyphor AG dropped as much as 21% Wednesday as the company shut down two phase III trials of its lead drug candidate, murepavadin, a first-in-class intravenous antibiotic in development for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).

LONDON – AM-Pharma BV has raised €116 million (US$130.7 million) in a series E round to fund phase III development of its recombinant alkaline phosphatase, Recap, in the treatment of sepsis-associated acute kidney injury (SA-AKI).

FDA clearance of Retrophin Inc.'s enteric-coated (EC) version of Thiola (tiopronin) 100-mg and 300-mg tablets for cystinuria – a rare, inherited disorder that causes levels of cystine to build up in urine, which leads to recurrent kidney stones – gave patients new dosing flexibility and set Wall Street abuzz about options for the San Diego-based firm as well.